entertainment -WSS

entertainment

author：focus 2025-09-06 03:53:43 - browse：1

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

WSS

Doctors on social media are being harassed and cyberbullied

Juul documents reveal insider tactics on political lobbying

Congress considering partial increase for doctor pay in Medicare

Why are elite athletes different? Take a look at their microbes

Latigo launches with $135 million for Vertex

Why are elite athletes different? Take a look at their microbes

focus

entertainment

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Death of patient in Alzheimer’s trial raises question of possible risks

Malaria cases in Florida and Texas: Here’s what you need to know

Report cites 'urgent' need to recruit more diverse clinical trial participants

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Amylyx, Aurinia, and IQVIA

State Dept. review finds Biden bears some blame for Afghanistan failures

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

In Memoriam: Notable people who died in 2023

Why are elite athletes different? Take a look at their microbes

explore

STAT's guide to the next generation of CAR

Why drug prescriptions should include diagnoses

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Disclosing genetic information: not as worrisome as once feared

Having children helps parents live longer, especially after age 80

Paxlovid study fails to answer questions over benefit for broader groups

focus

Wikipedia

focus

knowledge